Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

32.540
-0.480-1.45%
Volume:3.12M
Turnover:101.21M
Market Cap:11.52B
PE:-8.81
High:33.500
Open:33.500
Low:31.700
Close:33.020
52wk High:77.550
52wk Low:31.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:1.32
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.694
ROE:-23.04%
ROA:-9.09%
PB:2.58
PE(LYR):-8.81
PS:11.89

Loading ...

BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 Million

Reuters
·
Yesterday

Everest Med Enters Asset Purchase Agreement with Jixing Pharmaceutical Hong Kong

Stock News
·
Yesterday

Everest Medicines to Acquire Etripamil Nasal-Spray Assets from Corxel Pharmaceuticals for up to US$50.00 Million

Bulletin Express
·
Yesterday

Everest Medicines unit to acquire etripamil nasal spray assets for up to USD 50 million

Reuters
·
Yesterday

Everest Medicines - Assets Refers to Pharmaceutical Products That Uses Device to Deliver Etripamil by Nasal Spray

THOMSON REUTERS
·
Yesterday

Everest Medicines - Unit to Buy Assets for up to $50 Mln

THOMSON REUTERS
·
Yesterday

A Look At Everest Medicines (SEHK:1952) Valuation After Recent Share Price Pullback

Simply Wall St.
·
Mar 21

Everest MED to Acquire Full Ownership of Hasten with $200 Million Deposit, Targeting Southeast Asian Market of 600 Million

Deep News
·
Mar 19

EVEREST MED (01952) Places RMB200 Million Refundable Deposit for Potential Acquisition of Hasten’s Singapore Unit

Bulletin Express
·
Mar 17

Everest MED Considers Full Acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd.

Stock News
·
Mar 17

Everest Medicines signs LOI to buy Hasten Biopharmaceuticals (SG) and plans CNY200 million refundable deposit

Reuters
·
Mar 17

EVEREST MED Shares Climb Nearly 5% in Morning Session on Plans for Phase IIb Trial of Ophthalmic Drug VIS-101

Stock News
·
Mar 17

Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

prnewswire
·
Mar 13

EVEREST MED (01952) Sets 25 March 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express
·
Mar 10

Everest Medicines schedules board meeting to approve annual results for 2025

Reuters
·
Mar 10

EVEREST MED (01952) Announces Monthly Return for February 2026

Bulletin Express
·
Mar 05

EVEREST MED Shares Climb Over 5% in Morning Session Following Patent Victory for Innovative IgA Nephropathy Drug

Stock News
·
Mar 05

EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®

Stock News
·
Feb 27

EVEREST MED Shareholders Pass Key Commercialization Agreements at Special Meeting

Stock News
·
Feb 24

Everest Medicines (1952) Releases EGM Poll Results

Bulletin Express
·
Feb 24